Ikena therapeutics
Web7 mrt. 2024 · Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to … WebIkena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product …
Ikena therapeutics
Did you know?
WebIkena is redefining the targeted oncology landscape and envisioning a world in which every cancer patient has a cure, guided by a deep understanding of the patient experience and … Web2 nov. 2024 · Ikena is developing IK-930 as a potential targeted therapy for patients with cancers that exhibit genetic alterations across the Hippo pathway. IK-930 is designed to selectively bind TEAD and to disrupt TEAD-dependent transcription of key genes involved in cancer progression, metastases, and therapeutic resistance.
Web7 mrt. 2024 · Dr. Jeff Ecsedy, Ikena’s Chief Development Officer, will present data supporting the potential of IK-930 as a clinical agent during a minisymposium on experimental and molecular cancer therapeutics. WebOur Pipeline. As we evolve with our science, our multifaceted approach builds a robust pipeline of patient direct therapies. At Ikena™, we are advancing a portfolio of targeted …
Web28 nov. 2024 · Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in a … Web5 sep. 2024 · Arrys Therapeutics: ClinicalTrials.gov Identifier: NCT03658772 Other Study ID Numbers: ARYS-001 Keynote-878 ( Other Identifier: Merck Sharp & Dohme Corp. ) First Posted: September 5, 2024 Key Record Dates: Last Update Posted: April 22, 2024 Last Verified: April 2024
Web5 jan. 2024 · Their stock opened with $16.00 in its Mar 26, 2024 IPO. Ikena Oncology is funded by 12 investors. Bristol Myers Squibb and Cowen Healthcare Investments are the most recent investors. Ikena Oncology has a post-money valuation in the range of $500M to $1B as of Jan 6, 2024, according to PrivCo. Sign up for a free trial to view exact …
WebFounded Date 2014. Founders Sofie Qiao. Operating Status Active. Last Funding Type Series C. Legal Name Vivace Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel … tax rate 2023 companyWeb24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops … tax rate above 50 lakhsWebDescription. Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way. the crowding-out effect occurs when quizletWebCompanies include: Tango Therapeutics, Ikena Oncology, Intellia Therapeutics, Solid Bio, Mersana Therapeutics, and Shire. Responsible for full life cycle recruiting for all areas of … tax rate 2020 tableWeb14 mrt. 2024 · Ikena Oncology : Corporate Presentation - March 2024. We develop differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco- signaling network. Ikena Wholly Owned Pipeline Focused on Targeted Oncology in Hippo-Ras Oncosignaling Network. tax rate 2023 philippinesWebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known. tax rate 401k withdrawal calculatorWeb2 nov. 2024 · Preclinical research, including data presented by Ikena at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2024, suggests that IK-930 is a ... tax rate above annual allowance